Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure. The FDA has approved Hibsago (bepirovirsen), GSK’s ...
ViiV Healthcare has announced that Deborah Waterhouse is stepping down as chief executive officer of ViiV Healthcare and ...
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health ...
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the ...
METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals ...
METiS TechBio announced a strategic collaboration with Eli Lilly and Company focused on researching and discovering novel lipid nanoparticle (LNP)-based delivery solutions designed to enable ...
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data ...
Social listening can help medical affairs and medical information teams identify knowledge gaps, strengthen scientific exchange and respond to changing stakeholder needs faster and at greater scale.
Pharmaceutical Executive spoke with John Stanford, executive director at Incubate, about the current status of MFN and how ...
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results